Satraplatin
Title: Satraplatin
CAS Registry Number: 129580-63-8
CAS Name: (OC-6-43)-Bis(acetato-kO)amminedichloro(cyclohexanamine)-platinum
Additional Names: bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV)
Manufacturers' Codes: BMS-182751; BMY-45594; JM-216
Molecular Formula: C10H22Cl2N2O4Pt
Molecular Weight: 500.28
Percent Composition: C 24.01%, H 4.43%, Cl 14.17%, N 5.60%, O 12.79%, Pt 38.99%
Literature References: Orally active analog of cisplatin, q.v. Prepn: M. J. Abrams et al., EP 328274; eidem, US 5072011 (1989, 1991 both to Johnson Matthey). Clinical pharmacokinetics: S. Vouillamoz-Lorenz et al., Anticancer Res. 23, 2757 (2003). Clinical evaluation in small-cell lung cancer: E. Fokkema et al., J. Clin. Oncol. 17, 3822 (1999); in hormone-refractory prostate cancer: C. N. Sternberg et al., Oncology 68, 2 (2005). Review of clinical development: L. R. Kelland, Expert Opin. Invest. Drugs 9, 1373-1382 (2000).
Properties: Soly (mg/ml): water ~0.3; saline 0.4; 1-octanol 0.7. Partition coefficient (octanol/water): 0.1. LD50 in mice (mg/kg): 30 i.p.; 330 orally (Kelland).
Log P: Partition coefficient (octanol/water): 0.1
Toxicity data: LD50 in mice (mg/kg): 30 i.p.; 330 orally (Kelland)
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Platinum Complexes.

Others monographs:
BenzoxiquineVanadium TrifluorideRifalazilLimaprost
StreptodornaseThiocarbamizinetert-Butyl ChloroacetateSpiromesifen
α-PhenylacetamideTrimethyl BorateMethamphetamineHydrocinnamic Acid
ParamethasoneMetalaxylCadmium SelenateOnapristone
©2016 DrugLead US FDA&EMEA